Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

Next Previous
Trial Profile

A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EGL-003 (Primary)
  • Indications Atopic dermatitis; Autoimmune disorders; Cancer
  • Focus Adverse reactions; First in man
  • Sponsors Egle Therapeutics

Most Recent Events

  • 02 Dec 2025 Status changed from not yet recruiting to recruiting.
  • 02 Dec 2025 According to Egle Therapeutics SAS (Egle) media release, the company announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003 for atopic dermatitis.
  • 06 Oct 2025 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top